These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32852234)

  • 1. Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma.
    Chinen Y; Tanba K; Takagi R; Uchiyama H; Uoshima N; Shimura K; Fuchida SI; Kiyota M; Nakao M; Tsukamoto T; Shimura Y; Kobayashi T; Horiike S; Wada K; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M; Yokota I; Kuroda J;
    Leuk Lymphoma; 2020 Dec; 61(14):3378-3386. PubMed ID: 32852234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
    Tao L; Clarke CA; Rosenberg AS; Advani RH; Jonas BA; Flowers CR; Keegan THM
    Br J Haematol; 2017 Jul; 178(1):72-80. PubMed ID: 28542862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis.
    Jiang S; Zhen H; Jiang H
    Curr Probl Cancer; 2020 Feb; 44(1):100502. PubMed ID: 31537411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen.
    Neeman Y; Perry C; Silverman B; Waintraub N; Avivi I
    Leuk Lymphoma; 2020 Nov; 61(11):2638-2644. PubMed ID: 32611210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era.
    Lim RMH; Chan NPX; Khoo LP; Cheng CL; Tan L; Poon EYL; Somasundaram N; Farid M; Tang TPL; Tao M; Lim ST; Chan JY
    Sci Rep; 2020 Mar; 10(1):4373. PubMed ID: 32152442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.
    Fleury I; Chevret S; Pfreundschuh M; Salles G; Coiffier B; van Oers MH; Gisselbrecht C; Zucca E; Herold M; Ghielmini M; Thieblemont C
    Ann Oncol; 2016 Mar; 27(3):390-7. PubMed ID: 26681685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis.
    Major A; Smith DE; Ghosh D; Rabinovitch R; Kamdar M
    Cancer; 2020 Jan; 126(1):189-201. PubMed ID: 31509235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
    Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
    Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.
    Cho KM; Keam B; Ha H; Kim M; Jung JW; Song WJ; Kim TM; Jeon YK; Kang HR; Kim DW; Kim CW; Heo DS
    Korean J Intern Med; 2019 Jul; 34(4):885-893. PubMed ID: 29151283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP.
    Kadota T; Seo S; Fuse H; Ishii G; Itoh K; Yano T; Kaneko K; Tsukasaki K
    Cancer Med; 2019 Mar; 8(3):982-989. PubMed ID: 30730104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.
    Howlader N; Mariotto AB; Besson C; Suneja G; Robien K; Younes N; Engels EA
    Cancer; 2017 Sep; 123(17):3326-3334. PubMed ID: 28464214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).
    Lugtenburg PJ; de Nully Brown P; van der Holt B; D'Amore FA; Koene HR; de Jongh E; Fijnheer R; van Esser JW; Böhmer LH; Pruijt JF; Verhoef GE; Hoogendoorn M; Bilgin MY; Nijland M; van der Burg-de Graauw NC; Oosterveld M; Jie KG; Larsen TS; van der Poel MW; Leijs MB; Silbermann MH; van Marwijk Kooy M; Beeker A; Kersten MJ; Doorduijn JK; Tick LW; Brouwer RE; Lam KH; Burggraaff CN; de Keizer B; Arens AI; de Jong D; Hoekstra OS; Zijlstra-Baalbergen JM
    J Clin Oncol; 2020 Oct; 38(29):3377-3387. PubMed ID: 32730183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma.
    Amiot A; Jooste V; Gagniere C; Lévy M; Copie-Bergman C; Dupuis J; Le Baleur Y; Belhadj K; Sobhani I; Haioun C; Bouvier AM; Delchier JC
    Leuk Lymphoma; 2017 Sep; 58(9):1-11. PubMed ID: 28140708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
    Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
    Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma.
    Olszewski AJ; Mantripragada KC; Castillo JJ
    J Natl Compr Canc Netw; 2016 Sep; 14(9):1121-9. PubMed ID: 27587624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy.
    Sorigue M; Garcia O; Baptista MJ; Sancho JM; Tapia G; Mate JL; Feliu E; Navarro JT; Ribera JM
    Med Clin (Barc); 2017 Mar; 148(6):243-249. PubMed ID: 28038857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
    Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
    Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure.
    Hu S; Song Y; Sun X; Su L; Zhang W; Jia J; Bai O; Yang S; Liang R; Li X; Zhang H; Gao Y; Zhang W; Xiao X; Bao H; Wang N; Ren H; Cen X; Yang S; Zhao Y; Wang Y; Wang Y; Liu A; Wang J; Shi Y; Yuan M; Li Y; He X
    Cancer Sci; 2018 Dec; 109(12):3943-3952. PubMed ID: 30302857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.